Indication
Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Loading your page…
Loading your page…
Parkinson Disease
Marketing Authorisation Holder: Orion Corporation
EMA Authorisation: 11/11/2013
INN: levodopa;carbidopa;entacapone
AI Drug & Interaction Analysis
Free account required
Ask Osler about Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz): drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.